Our compounds
Pipeline
PSYCHIATRY
BIPOLAR DEPRESSION with SUICIDAL IDEATION
Indication
Compound Name
Phase
Submission Type
Compound Type
Severe Bipolar Depression in patients with Acute Suicidal Ideation & Behavior (ASIB)
FDA SPA, Breakthrough Therapy Designation, Biomarker Letter of Support
Data Readout Expected Q3 2023
FDA SPA, Breakthrough Therapy Designation, Biomarker Letter of Support
Data Readout Expected Q3 2023
NRX-100/NRX-101™
Phase 3
NDA
Sequential Therapy for the Treatment of Severe Bipolar Depression.
Status
Completed
Study Results
No Results Available
Locations
Research Site, Birmingham, Birmingham, Alabama, United States | Research Site, Charlotte, Charlotte, North Carolina, United States | Research Site, Houston, Houston, Texas, United States
Clinical Trial
Indication
Compound Name
Phase
Submission Type
Compound Type
Severe Bipolar Depression with Sub-Acute Suicidal Ideation
& Behavior (SSIB)
Currently Enrolling
Data Readout Expected Q1 2023
& Behavior (SSIB)
Currently Enrolling
Data Readout Expected Q1 2023
NRX-101™
Phase 2
NDA
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
Status
Recruiting
Study Results
No Results Available
Locations
JP Smith Hospital, Fort Worth, Texas, United States | Research Centers of America, Hollywood, Florida, United States | Research Site, Birmingham, Birmingham, Alabama, United States | Research Site, Houston, Houston, Texas, United States | Texas Health Hospital Frisco, Frisco, Texas, United States | University of California – Irvine, Irvine, California, United States | University of Louisville Hospital, Louisville, Kentucky, United States | University of Utah Health (Site 211-002), 419 Wakara Way, Ste. 207, Salt Lake City, Utah, United States
Clinical Trial
POST TRAUMATIC STRESS DISORDER (PTSD)
Indication
Compound Name
Phase
Submission Type
Compound Type
PTSD in patients with Depression & Suicidality
Pending
P2 Trial Initiation and Data Readout Expected in 2023
Pending
P2 Trial Initiation and Data Readout Expected in 2023
NRX-101™
Phase 1
NDA
Study Results
No Study Results
Expanded Access Policy on RTT: NRX-101 is not currently available outside of clinical trials.
Follow Us
Keep up with the latest news and updates about NRx through social media.